235 related articles for article (PubMed ID: 10848718)
21. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
Carmichael SJ; Beal J; Day RO; Tett SE
J Rheumatol; 2002 Oct; 29(10):2077-83. PubMed ID: 12375315
[TBL] [Abstract][Full Text] [Related]
23. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
24. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
[TBL] [Abstract][Full Text] [Related]
25. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
[TBL] [Abstract][Full Text] [Related]
26. Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.
Ehret GB; Daali Y; Chabert J; Rebsamen M; Wolff A; Forster A; Moursli F; Fritschy D; Rossier MF; Piguet V; Dayer P; Gex-Fabry M; Desmeules JA
Pain Physician; 2013 Jan; 16(1):45-56. PubMed ID: 23340533
[TBL] [Abstract][Full Text] [Related]
27. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction.
Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
J Clin Pharmacol; 2010 Feb; 50(2):214-25. PubMed ID: 19948945
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
Huang J; Chuang SK; Cheng CL; Lai ML
Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
[TBL] [Abstract][Full Text] [Related]
29. Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.
Kaila N; Straka RJ; Brundage RC
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):141-56. PubMed ID: 17053980
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael SJ; Charles B; Tett SE
Ther Drug Monit; 2003 Dec; 25(6):671-81. PubMed ID: 14639053
[TBL] [Abstract][Full Text] [Related]
31. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Solomon DH; Garg R; Lu B; Todd DJ; Mercer E; Norton T; Massarotti E
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1246-51. PubMed ID: 24470436
[TBL] [Abstract][Full Text] [Related]
32. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women.
Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
J Pharmacol Exp Ther; 2005 Jun; 313(3):1172-81. PubMed ID: 15718288
[TBL] [Abstract][Full Text] [Related]
33. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Ozdemir M; Crewe KH; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2004 Dec; 44(12):1398-404. PubMed ID: 15545311
[TBL] [Abstract][Full Text] [Related]
34. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
Rau T; Heide R; Bergmann K; Wuttke H; Werner U; Feifel N; Eschenhagen T
Pharmacogenetics; 2002 Aug; 12(6):465-72. PubMed ID: 12172215
[TBL] [Abstract][Full Text] [Related]
35. The antitussive effect of dextromethorphan in relation to CYP2D6 activity.
Abdul Manap R; Wright CE; Gregory A; Rostami-Hodjegan A; Meller ST; Kelm GR; Lennard MS; Tucker GT; Morice AH
Br J Clin Pharmacol; 1999 Sep; 48(3):382-7. PubMed ID: 10510150
[TBL] [Abstract][Full Text] [Related]
36. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.
Stout SM; Nielsen J; Welage LS; Shea M; Brook R; Kerber K; Bleske BE
J Clin Pharmacol; 2011 Mar; 51(3):389-96. PubMed ID: 20400652
[TBL] [Abstract][Full Text] [Related]
37. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
38. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.
Cho DY; Bae SH; Lee JK; Park JB; Kim YW; Lee S; Oh E; Kim BT; Bae SK
Xenobiotica; 2015 Mar; 45(3):256-63. PubMed ID: 25268386
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS.
Borkar RM; Bhandi MM; Dubey AP; Ganga Reddy V; Komirishetty P; Nandekar PP; Sangamwar AT; Kamal A; Banerjee SK; Srinivas R
Biomed Chromatogr; 2016 Oct; 30(10):1556-72. PubMed ID: 27006091
[TBL] [Abstract][Full Text] [Related]
40. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
